JP2007505922A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007505922A5 JP2007505922A5 JP2006527059A JP2006527059A JP2007505922A5 JP 2007505922 A5 JP2007505922 A5 JP 2007505922A5 JP 2006527059 A JP2006527059 A JP 2006527059A JP 2006527059 A JP2006527059 A JP 2006527059A JP 2007505922 A5 JP2007505922 A5 JP 2007505922A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- amino
- acyloxy
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004423 acyloxy group Chemical group 0.000 claims 51
- 125000002252 acyl group Chemical group 0.000 claims 46
- 125000000217 alkyl group Chemical group 0.000 claims 44
- 150000002431 hydrogen Chemical class 0.000 claims 44
- 229910052739 hydrogen Inorganic materials 0.000 claims 44
- 239000001257 hydrogen Substances 0.000 claims 44
- 150000001875 compounds Chemical class 0.000 claims 41
- 125000000547 substituted alkyl group Chemical group 0.000 claims 41
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 40
- 229910052717 sulfur Inorganic materials 0.000 claims 31
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 30
- 239000011593 sulfur Substances 0.000 claims 30
- -1 Amino, substituted amino Chemical group 0.000 claims 29
- 229910052736 halogen Inorganic materials 0.000 claims 26
- 150000002367 halogens Chemical class 0.000 claims 26
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 26
- 125000003545 alkoxy group Chemical group 0.000 claims 25
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 25
- 125000003118 aryl group Chemical group 0.000 claims 24
- 125000003342 alkenyl group Chemical group 0.000 claims 23
- 125000000304 alkynyl group Chemical group 0.000 claims 23
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 23
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 23
- 125000003107 substituted aryl group Chemical group 0.000 claims 23
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 17
- 229910052760 oxygen Inorganic materials 0.000 claims 17
- 239000001301 oxygen Substances 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 12
- ZNXFEZJRALUZGZ-UHFFFAOYSA-N 2-(2-oxo-6-sulfanylidenepiperidin-3-yl)-3-sulfanylideneisoindol-1-one Chemical compound S=C1C2=CC=CC=C2C(=O)N1C1CCC(=S)NC1=O ZNXFEZJRALUZGZ-UHFFFAOYSA-N 0.000 claims 8
- HPZIYTPFXVRSEL-UHFFFAOYSA-N 2-[2,6-bis(sulfanylidene)piperidin-3-yl]-3-sulfanylideneisoindol-1-one Chemical compound S=C1C2=CC=CC=C2C(=O)N1C1CCC(=S)NC1=S HPZIYTPFXVRSEL-UHFFFAOYSA-N 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- YIVPAGQZXIJWBX-UHFFFAOYSA-N 2-[2,6-bis(sulfanylidene)piperidin-3-yl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=S)NC1=S YIVPAGQZXIJWBX-UHFFFAOYSA-N 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- GXIXKSMAOXPPGZ-UHFFFAOYSA-N 2-cyclohex-3-en-1-ylisoindole-1,3-dithione Chemical compound S=C1C2=CC=CC=C2C(=S)N1C1CCC=CC1 GXIXKSMAOXPPGZ-UHFFFAOYSA-N 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 3
- QFSZJXRBCXUCMD-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)pyrrolo[3,4-c]pyridine-1,3-dione Chemical compound O=C1C2=CN=CC=C2C(=O)N1C1CCC(=O)NC1=O QFSZJXRBCXUCMD-UHFFFAOYSA-N 0.000 claims 3
- FNFLWRDNFCUNQT-UHFFFAOYSA-N 2-(2-oxo-6-sulfanylidenepiperidin-3-yl)isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=S)NC1=O FNFLWRDNFCUNQT-UHFFFAOYSA-N 0.000 claims 3
- OTDLWDKISPNCQW-UHFFFAOYSA-N 2-[2,6-dioxo-1-(2-phenylethyl)piperidin-3-yl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C(C1=O)CCC(=O)N1CCC1=CC=CC=C1 OTDLWDKISPNCQW-UHFFFAOYSA-N 0.000 claims 3
- VDXNOKQEYGTPGZ-UHFFFAOYSA-N 2-cyclohex-3-en-1-yl-3-sulfanylideneisoindol-1-one Chemical compound S=C1C2=CC=CC=C2C(=O)N1C1CCC=CC1 VDXNOKQEYGTPGZ-UHFFFAOYSA-N 0.000 claims 3
- FVOWJCUUOBMLPE-UHFFFAOYSA-N 3-(1-oxo-3-sulfanylideneisoindol-2-yl)piperidine-2,6-dione Chemical compound S=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O FVOWJCUUOBMLPE-UHFFFAOYSA-N 0.000 claims 3
- QOVMQFRFRYWHFV-UHFFFAOYSA-N 3-n-(2,6-dioxopiperidin-3-yl)naphthalene-2,3-dicarboxamide Chemical compound NC(=O)C1=CC2=CC=CC=C2C=C1C(=O)NC1CCC(=O)NC1=O QOVMQFRFRYWHFV-UHFFFAOYSA-N 0.000 claims 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 3
- KZVNYZQKCAGNHL-UHFFFAOYSA-N [2-[(2,6-dioxopiperidin-3-yl)carbamoyl]phenyl] acetate Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1C(=O)NC(=O)CC1 KZVNYZQKCAGNHL-UHFFFAOYSA-N 0.000 claims 3
- 125000001931 aliphatic group Chemical group 0.000 claims 3
- DZVUHHROHSPUED-UHFFFAOYSA-N dimethyl 2-(1-oxo-3-sulfanylideneisoindol-2-yl)pentanedioate Chemical compound C1=CC=C2C(=S)N(C(CCC(=O)OC)C(=O)OC)C(=O)C2=C1 DZVUHHROHSPUED-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 2
- DNYJMSSHPMBPGB-UHFFFAOYSA-N 2-(1-oxo-3-sulfanylideneisoindol-2-yl)pentanedioic acid Chemical compound C1=CC=C2C(=S)N(C(CCC(=O)O)C(O)=O)C(=O)C2=C1 DNYJMSSHPMBPGB-UHFFFAOYSA-N 0.000 claims 2
- IOLMYDDAHXTLLS-UHFFFAOYSA-N 3-aminopiperidine-2,6-dione;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NC1CCC(=O)NC1=O IOLMYDDAHXTLLS-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- NPWMTBZSRRLQNJ-UHFFFAOYSA-N pyroglutamine Chemical compound NC1CCC(=O)NC1=O NPWMTBZSRRLQNJ-UHFFFAOYSA-N 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 229960003433 thalidomide Drugs 0.000 claims 2
- VVNYDCGZZSTUBC-LURJTMIESA-N (2s)-5-amino-2-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCC(N)=O VVNYDCGZZSTUBC-LURJTMIESA-N 0.000 claims 1
- PAMWIQZMLLUFBP-UHFFFAOYSA-N 1-aminopiperidine-2,6-dione Chemical compound NN1C(=O)CCCC1=O PAMWIQZMLLUFBP-UHFFFAOYSA-N 0.000 claims 1
- MBYLNRRTUYQZAW-UHFFFAOYSA-N 2-(2-phenylethyl)isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1CCC1=CC=CC=C1 MBYLNRRTUYQZAW-UHFFFAOYSA-N 0.000 claims 1
- GWSCZWXCPVOCOC-UHFFFAOYSA-N 2-benzyl-3-benzyliminoisoindol-1-one Chemical compound C=1C=CC=CC=1CN=C1C2=CC=CC=C2C(=O)N1CC1=CC=CC=C1 GWSCZWXCPVOCOC-UHFFFAOYSA-N 0.000 claims 1
- ZIKDETHPMRZUKO-UHFFFAOYSA-N 2-cyclohex-3-en-1-ylisoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC=CC1 ZIKDETHPMRZUKO-UHFFFAOYSA-N 0.000 claims 1
- QFODIVSHCUILDZ-UHFFFAOYSA-N 3-(3-oxoisoindol-1-ylidene)piperidine-2,6-dione Chemical compound C12=CC=CC=C2C(=O)NC1=C1CCC(=O)NC1=O QFODIVSHCUILDZ-UHFFFAOYSA-N 0.000 claims 1
- JTZRBPSHQZOCBU-UHFFFAOYSA-N 6-sulfanylidenepiperidin-2-one Chemical compound O=C1CCCC(=S)N1 JTZRBPSHQZOCBU-UHFFFAOYSA-N 0.000 claims 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 claims 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 claims 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-L glutarate(2-) Chemical compound [O-]C(=O)CCCC([O-])=O JFCQEDHGNNZCLN-UHFFFAOYSA-L 0.000 claims 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- CMTSCLKCQBPLSH-UHFFFAOYSA-N isoindole-1,3-dithione Chemical compound C1=CC=C2C(=S)NC(=S)C2=C1 CMTSCLKCQBPLSH-UHFFFAOYSA-N 0.000 claims 1
- ABLCLJKCIOWZAQ-UHFFFAOYSA-N piperidine-2,3,6-trione Chemical compound O=C1CCC(=O)NC1=O ABLCLJKCIOWZAQ-UHFFFAOYSA-N 0.000 claims 1
- ICJTYWLQSDUPRA-UHFFFAOYSA-N piperidine-2,6-dithione Chemical compound S=C1CCCC(=S)N1 ICJTYWLQSDUPRA-UHFFFAOYSA-N 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 0 CC(C)C(CC(*)C(*)C1=C(C*=C2*)[N+]([O-])=O)C1=C2O Chemical compound CC(C)C(CC(*)C(*)C1=C(C*=C2*)[N+]([O-])=O)C1=C2O 0.000 description 6
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50472403P | 2003-09-17 | 2003-09-17 | |
| US60/504,724 | 2003-09-17 | ||
| PCT/US2004/030506 WO2005028436A2 (en) | 2003-09-17 | 2004-09-17 | Thalidomide analogs as tnf-alpha modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007505922A JP2007505922A (ja) | 2007-03-15 |
| JP2007505922A5 true JP2007505922A5 (enExample) | 2007-10-11 |
| JP4943845B2 JP4943845B2 (ja) | 2012-05-30 |
Family
ID=34375538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006527059A Expired - Fee Related JP4943845B2 (ja) | 2003-09-17 | 2004-09-17 | サリドマイド類似体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7973057B2 (enExample) |
| EP (1) | EP1663223B1 (enExample) |
| JP (1) | JP4943845B2 (enExample) |
| CN (1) | CN1867331B (enExample) |
| AU (1) | AU2004274474B2 (enExample) |
| BR (1) | BRPI0414497A (enExample) |
| CA (2) | CA2808646C (enExample) |
| SG (1) | SG133603A1 (enExample) |
| WO (1) | WO2005028436A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2929331B2 (ja) * | 1990-07-18 | 1999-08-03 | 丸善石油化学株式会社 | トラクションドライブ用流体 |
| UA91341C2 (ru) | 2004-07-15 | 2010-07-26 | Амр Текнолоджи, Інк. | Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина |
| CN100383139C (zh) * | 2005-04-07 | 2008-04-23 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物 |
| CN1939922B (zh) * | 2005-09-27 | 2010-10-13 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物 |
| WO2007136640A2 (en) * | 2006-05-16 | 2007-11-29 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
| US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| AU2007290407A1 (en) * | 2006-08-30 | 2008-03-06 | Celgene Corporation | 5-substituted isoindoline compounds |
| CA2681633C (en) * | 2007-03-20 | 2018-01-09 | Celgene Corporation | 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same |
| AU2013260742B2 (en) * | 2007-03-20 | 2016-06-16 | Celgene Corporation | 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same |
| US7723301B2 (en) * | 2007-08-29 | 2010-05-25 | The Board Of Trustees Of The University Of Arkansas | Pharmaceutical compositions comprising an anti-teratogenic compound and applications of the same |
| US20090298882A1 (en) * | 2008-05-13 | 2009-12-03 | Muller George W | Thioxoisoindoline compounds and compositions comprising and methods of using the same |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| JP5739415B2 (ja) | 2009-05-12 | 2015-06-24 | ブリストル−マイヤーズ スクウィブ カンパニー | （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用 |
| CN102595902B (zh) * | 2009-05-12 | 2015-04-29 | 阿尔巴尼分子研究公司 | 7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途 |
| ES2446971T3 (es) | 2009-05-12 | 2014-03-11 | Albany Molecular Research, Inc. | Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso |
| SG183257A1 (en) | 2010-02-11 | 2012-09-27 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| ES2664872T3 (es) * | 2010-06-18 | 2018-04-23 | Taiho Pharmaceutical Co., Ltd | Moduladores PRPK-TPRKB y sus usos |
| US8927725B2 (en) | 2011-12-02 | 2015-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thio compounds |
| JP2015500001A (ja) | 2011-12-14 | 2015-01-05 | 大鵬薬品工業株式会社 | 組換えｐｒｐｋ−ｔｐｒｋｂ及びその使用 |
| US9383644B2 (en) | 2014-09-18 | 2016-07-05 | Heraeus Precious Metals North America Daychem LLC | Sulfonic acid derivative compounds as photoacid generators in resist applications |
| NZ731789A (en) | 2014-10-30 | 2019-04-26 | Kangpu Biopharmaceuticals Ltd | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof |
| US9477150B2 (en) | 2015-03-13 | 2016-10-25 | Heraeus Precious Metals North America Daychem LLC | Sulfonic acid derivative compounds as photoacid generators in resist applications |
| EP3319603B1 (en) * | 2015-07-08 | 2021-11-17 | Gilrose Pharmaceuticals, LLC | Use of methylphenidate for the treatment of gait and limb impairment secondary to pre-frontal cortex processing disorder |
| CA3000661C (en) | 2015-09-30 | 2024-04-02 | Nigel H. Greig | Thalidomide analogs and methods of use |
| CN109153644B (zh) | 2016-03-16 | 2022-10-21 | H·李·莫菲特癌症中心研究有限公司 | 用以增强效应t细胞功能的针对cereblon的小分子 |
| WO2018095377A1 (zh) * | 2016-11-24 | 2018-05-31 | 天津和美生物技术有限公司 | 哌啶-2,6-二酮衍生物以及溃疡性结肠炎的治疗 |
| SG11202003415XA (en) | 2017-10-18 | 2020-05-28 | Novartis Ag | Compositions and methods for selective protein degradation |
| EP3820532A4 (en) | 2018-07-11 | 2022-04-06 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | DIMERE IMMUNOMODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS |
| US11324731B2 (en) | 2018-09-13 | 2022-05-10 | City Of Hope | TXNIP-TRX complex inhibitors and methods of using the same |
| JP2022507267A (ja) | 2018-11-13 | 2022-01-18 | バイオセリックス， インコーポレイテッド | 置換イソインドリノン |
| WO2020124500A1 (zh) * | 2018-12-20 | 2020-06-25 | 江苏凯迪恩医药科技有限公司 | 一种含氮杂环化合物、其制备方法及应用 |
| EP3932922A4 (en) | 2019-02-25 | 2022-05-11 | ShanghaiTech University | SULPHUR-CONTAINING COMPOUND BASED ON A GLUTARIMIDE FRAMEWORK AND ITS USE |
| WO2020219742A1 (en) | 2019-04-24 | 2020-10-29 | Novartis Ag | Compositions and methods for selective protein degradation |
| WO2021023233A1 (zh) | 2019-08-05 | 2021-02-11 | 上海科技大学 | Egfr蛋白降解剂及其抗肿瘤应用 |
| AU2020336381A1 (en) * | 2019-08-27 | 2022-03-03 | The Regents Of The University Of Michigan | Cereblon E3 ligase inhibitors |
| KR102783667B1 (ko) | 2019-10-24 | 2025-03-21 | 삼성전자 주식회사 | 전자 장치 및 그의 디스플레이 동작 제어 방법 |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| WO2021143822A1 (zh) * | 2020-01-16 | 2021-07-22 | 江苏恒瑞医药股份有限公司 | 并环酰亚胺类衍生物、其制备方法及其在医药上的应用 |
| AU2021226514B2 (en) * | 2020-02-25 | 2023-10-19 | Shanghaitech University | Glutarimide skeleton-based compounds and application thereof |
| KR102943446B1 (ko) * | 2020-10-26 | 2026-04-01 | 주식회사 아이비스바이오 | 포말리도마이드로부터 3,6'-디티오포말리도마이드를 선택적으로 합성하는 방법 |
| WO2022187423A1 (en) * | 2021-03-03 | 2022-09-09 | The Regents Of The University Of Michigan | Cereblon ligands |
| EP4484417A4 (en) * | 2022-02-25 | 2026-01-14 | Aevis Bio Inc | NEW POMALIDOMIDE DERIVATIVE, ITS PREPARATION PROCESS AND ITS USE |
| CN120129677A (zh) | 2022-11-04 | 2025-06-10 | 百时美施贵宝公司 | 化合物及其用于治疗血红素病变的用途 |
| WO2025016351A1 (zh) * | 2023-07-14 | 2025-01-23 | 标新生物医药科技(上海)有限公司 | 基于硫代的戊二酰亚胺基异吲哚啉酮骨架的化合物及其应用 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2830991A (en) | 1954-05-17 | 1958-04-15 | Gruenenthal Chemie | Products of the amino-piperidine-2-6-dione series |
| GB962857A (en) | 1961-12-04 | 1964-07-08 | Distillers Co Yeast Ltd | Process for the production of imides |
| GB1049283A (en) * | 1962-04-14 | 1966-11-23 | Distillers Co Yeast Ltd | Substituted butyro-lactones and -thiolactones |
| US3320270A (en) * | 1963-10-08 | 1967-05-16 | Tri Kem Corp | Certain 2-acylimidothiazole compounds |
| US3314953A (en) | 1964-03-16 | 1967-04-18 | Richardson Merrell Inc | 1-substituted-3-phthalimido-2, 5-dioxopyrrolidines |
| IL25595A (en) | 1965-05-08 | 1971-01-28 | Gruenenthal Chemie | New history of cyclic amide compounds and process for the production of these compounds |
| US3560495A (en) | 1965-05-08 | 1971-02-02 | Ernst Frankus | 1-heterocyclic amino methyl or 1-heterocyclic hydrazino methyl-3-phthalimido or (3',6'-dithia-3',4',5',6'-tetrahydrophthalimido)-pyrrolidinediones-2,5 or piperidinediones-2,6 |
| GB1324718A (en) * | 1970-11-10 | 1973-07-25 | Nehezvegyipari Kutato Intezet | Phthalimido triazines |
| US4067718A (en) | 1975-11-12 | 1978-01-10 | American Cyanamid Company | Method for controlling the relative stem growth of plants |
| US4291048A (en) | 1978-07-06 | 1981-09-22 | Joseph Gold | Method of treating tumors and cancerous cachexia with L-tryptophan |
| US5354690A (en) | 1989-07-07 | 1994-10-11 | Karl Tryggvason | Immunological methods for the detection of the human type IV collagen α5 chain |
| US5902790A (en) | 1995-10-03 | 1999-05-11 | Cytran, Inc. | Pharmaceutical angiostatic dipeptide compositions and method of use thereof |
| GB9311281D0 (en) | 1993-06-01 | 1993-07-21 | Rhone Poulenc Rorer Ltd | Novel composition of matter |
| EP0580641B1 (de) | 1991-04-17 | 1996-12-27 | Grünenthal GmbH | Neue thalidomidderivate, ein verfahren zu deren herstellung sowie die verwendung derselben in arzneimitteln |
| US6096768A (en) | 1992-01-28 | 2000-08-01 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group |
| US20010056114A1 (en) | 2000-11-01 | 2001-12-27 | D'amato Robert | Methods for the inhibition of angiogenesis with 3-amino thalidomide |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US6228879B1 (en) | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
| US5434170A (en) | 1993-12-23 | 1995-07-18 | Andrulis Pharmaceuticals Corp. | Method for treating neurocognitive disorders |
| US5443824A (en) | 1994-03-14 | 1995-08-22 | Piacquadio; Daniel J. | Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions |
| DE4422237A1 (de) | 1994-06-24 | 1996-01-04 | Gruenenthal Gmbh | Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe |
| US5789434A (en) | 1994-11-15 | 1998-08-04 | Bayer Corporation | Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors |
| WO1996020705A1 (en) | 1994-12-30 | 1996-07-11 | Celgene Corporation | IMMUNOTHERAPEUTIC IMIDES/AMIDES AND THEIR USE FOR REDUCING LEVELS OF TNF$g(a) |
| US6429221B1 (en) | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
| US5783605A (en) | 1995-02-27 | 1998-07-21 | Kuo; Sheng-Chu | Helper inducers for differentiation therapy and chemoprevention of cancer |
| US5728844A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
| DE19613976C1 (de) | 1996-04-09 | 1997-11-20 | Gruenenthal Gmbh | Thalidomid-Prodrugs mit immunmodulatorischer Wirkung |
| CA2251060C (en) | 1996-04-09 | 2006-09-12 | Grunenthal Gmbh | Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action |
| WO1997045117A1 (en) | 1996-05-29 | 1997-12-04 | Prototek, Inc. | Prodrugs of thalidomide and methods for using same as modulators of t-cell function |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| DE69740140D1 (de) | 1996-07-24 | 2011-04-14 | Celgene Corp | Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen |
| EP1920773B1 (en) | 1996-11-05 | 2011-01-05 | The Children's Medical Center Corporation | Thalidomide and dexamethasone for the treatment of tumors |
| KR20000069431A (ko) | 1996-12-13 | 2000-11-25 | 피터 지. 스트링거 | Ｐｓａ의 효소 활성 억제제 |
| DE19703763C1 (de) | 1997-02-01 | 1998-10-01 | Gruenenthal Gmbh | Thalidomidanaloge Verbindungen aus der Klasse der Piperidin-2,6-Dione |
| RU2108786C1 (ru) | 1997-09-15 | 1998-04-20 | Клавдия Степановна Евланенкова | Средство для лечения онкологических больных |
| DE19743968C2 (de) | 1997-10-06 | 2002-07-11 | Gruenenthal Gmbh | Intravenöse Applikationsform von Thalidomid zur Therapie immunologischer Erkrankungen |
| WO1999058096A2 (en) | 1998-05-11 | 1999-11-18 | Entremed, Inc. | Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis |
| IL139710A (en) | 1998-05-15 | 2005-07-25 | Astazeneca Ab | Benzamide derivatives for the treatment of diseases mediated by cytokines |
| DE19843793C2 (de) | 1998-09-24 | 2000-08-03 | Gruenenthal Gmbh | Substituierte Benzamide |
| US20030013739A1 (en) | 1998-12-23 | 2003-01-16 | Pharmacia Corporation | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia |
| DK1040838T3 (da) | 1999-03-31 | 2003-05-26 | Gruenenthal Gmbh | Stabil vandig opløsning af 3-(1-oxo-1,3-dihydroisoindol-2-yl )piperidin-2,6-dion |
| WO2001041755A2 (en) | 1999-12-02 | 2001-06-14 | The Regents Of The University Of Michigan | Topical compositions comprising thalidomide for the treatment of inflammatory diseases |
| US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| CA2430669C (en) | 2000-11-30 | 2011-06-14 | The Children's Medical Center Corporation | Synthesis of 3-amino-thalidomide and its enantiomers |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| JP4361273B2 (ja) * | 2001-02-27 | 2009-11-11 | アメリカ合衆国 | 潜在的な血管形成阻害剤としてのサリドマイド類似体 |
| DE60231989D1 (de) | 2001-08-06 | 2009-05-28 | Childrens Medical Center | Antiangiogenese wirkung von stickstoffsubstituierten thalidomid-analoga |
| EP1336602A1 (en) * | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
| DK1505973T3 (da) | 2002-05-17 | 2010-05-31 | Celgene Corp | Kombinationer til behandling af multipelt myelom |
| CN100488959C (zh) | 2003-03-27 | 2009-05-20 | 天津和美生物技术有限公司 | 水溶性的酞胺哌啶酮衍生物 |
| WO2005016326A2 (en) | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
-
2004
- 2004-09-17 CA CA2808646A patent/CA2808646C/en not_active Expired - Fee Related
- 2004-09-17 US US10/572,485 patent/US7973057B2/en not_active Expired - Fee Related
- 2004-09-17 AU AU2004274474A patent/AU2004274474B2/en not_active Ceased
- 2004-09-17 SG SG200704530-5A patent/SG133603A1/en unknown
- 2004-09-17 WO PCT/US2004/030506 patent/WO2005028436A2/en not_active Ceased
- 2004-09-17 EP EP04784385.9A patent/EP1663223B1/en not_active Expired - Lifetime
- 2004-09-17 CA CA2538864A patent/CA2538864C/en not_active Expired - Fee Related
- 2004-09-17 CN CN2004800268113A patent/CN1867331B/zh not_active Expired - Fee Related
- 2004-09-17 JP JP2006527059A patent/JP4943845B2/ja not_active Expired - Fee Related
- 2004-09-17 BR BRPI0414497-0A patent/BRPI0414497A/pt not_active IP Right Cessation
-
2011
- 2011-06-03 US US13/153,355 patent/US8546430B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI354666B (en) | Heterocyclic aspartyl protease inhibitors | |
| RU2005137403A (ru) | Новые замещенные 3-сера-индолы | |
| JP2005535586A5 (enExample) | ||
| JP2018511587A5 (enExample) | ||
| JP2007519695A5 (enExample) | ||
| RU2219179C2 (ru) | Азациклические соединения, фармацевтические композиции | |
| RU2007118632A (ru) | Ингибиторы митотического кинезина и способы их использования | |
| RU2005136368A (ru) | Производные пиперазина и их применение для лечения неврологических и психиатрических заболеваний | |
| JP2005504039A5 (enExample) | ||
| JP2008535803A5 (enExample) | ||
| RU2012134306A (ru) | Азотосодержащие производные гетероарилов | |
| JP2005526076A5 (enExample) | ||
| JP2006524222A5 (enExample) | ||
| JP2005538955A5 (enExample) | ||
| RU2008126391A (ru) | Производные 1,5-замещенного индол-2-иламида | |
| JP2002534519A5 (enExample) | ||
| RU2005104434A (ru) | Производные 1-гетероциклилалкил-3-сульфонилиндола или - индазола как лиганды 5-гидрокситриптамина-6 | |
| JP2005518414A5 (enExample) | ||
| JP2007505922A (ja) | サリドマイド類似体 | |
| RU2007124545A (ru) | Производные [4-(гетероарил)пиперазин-1-ил]-(2,5-замещенный фенил)метанона в качестве ингибиторов переносчика глицина-1 (glyt-1) для лечения неврологических и психоневрологических заболеваний | |
| JP2022549222A5 (enExample) | ||
| RU2000105266A (ru) | Производные 1-(n-фениламиноалкил)-пиперазина, замещенные в положении 2 фенильного кольца | |
| JP2002030084A5 (enExample) | ||
| JP2018515489A5 (enExample) | ||
| JP2020500192A5 (enExample) |